TOPAMAX Drug Patent Profile

Which patents cover Topamax, and what generic alternatives are available?

Topamax is a drug marketed by Janssen Pharms and is included in two NDAs.

The generic ingredient in TOPAMAX is topiramate. There are twenty-six drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the topiramate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Topamax

A generic version of TOPAMAX was approved as topiramate by ACCORD HLTHCARE on March 27^th, 2009.

Summary for TOPAMAX

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	86
Patent Applications:	4,852
Drug Prices:	Drug price information for TOPAMAX
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TOPAMAX
What excipients (inactive ingredients) are in TOPAMAX?	TOPAMAX excipients list
DailyMed Link:	TOPAMAX at DailyMed

See drug prices for TOPAMAX

See drug sales revenues for TOPAMAX

Recent Clinical Trials for TOPAMAX

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
All India Institute of Medical Sciences, Bhubaneswar	Phase 4
Stanford University	Early Phase 1
Université de Sherbrooke	Phase 4

See all TOPAMAX clinical trials

Pharmacology for TOPAMAX

Mechanism of Action	Cytochrome P450 2C19 Inhibitors Cytochrome P450 3A4 Inducers
Physiological Effect	Decreased Central Nervous System Disorganized Electrical Activity

Paragraph IV (Patent) Challenges for TOPAMAX

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TOPAMAX	Tablets	topiramate	50 mg	020505	1	2005-09-08
TOPAMAX	Tablets	topiramate	25 mg, 100 mg and 200 mg	020505		2001-12-26

US Patents and Regulatory Information for TOPAMAX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Pharms	TOPAMAX	topiramate	CAPSULE;ORAL	020844-001	Oct 26, 1998	AB	RX	Yes	No
Janssen Pharms	TOPAMAX	topiramate	TABLET;ORAL	020505-003	Dec 24, 1996		DISCN	No	No
Janssen Pharms	TOPAMAX	topiramate	TABLET;ORAL	020505-005	Dec 24, 1996	AB	RX	Yes	No
Janssen Pharms	TOPAMAX	topiramate	TABLET;ORAL	020505-006	Dec 24, 1996		DISCN	No	No
Janssen Pharms	TOPAMAX	topiramate	CAPSULE;ORAL	020844-002	Oct 26, 1998	AB	RX	Yes	Yes
Janssen Pharms	TOPAMAX	topiramate	TABLET;ORAL	020505-004	Dec 24, 1996	AB	RX	Yes	No

International Patents for TOPAMAX

See the table below for patents covering TOPAMAX around the world.

Country	Patent Number	Title	Estimated Expiration
Estonia	04175	Meetod topiramaadi farmatseutilise kompositsioonivalmistamiseks, farmatseutiline kompositsioon ning topiramaadi kasutamine diabeedi raviks ette nähtud ravimi valmistamiseks
Finland	79095
Estonia	200000503
Malaysia	125821	PHARMACEUTICAL COMPOSITION OF TOPIRAMATE
Israel	138032	PHARMACEUTICAL COMPOSITION OF TOPIRAMATE
Germany	69910186

Supplementary Protection Certificates for TOPAMAX

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0138441	SPC/GB95/028	United Kingdom		PRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718
2317997	2190050-1	Sweden		PRODUCT NAME: PHENTERMINE AND TOPIRAMATE; NAT. REG. NO/DATE: 59574-59577 20210617; FIRST REG.: IS IS/1/21/018/01-04 20210212
0138441	97C0097	Belgium		PRODUCT NAME: TOPIRAMAAT; NAT. REGISTRATION NO/DATE: 1028 IS 71 F 3 19970616; FIRST REGISTRATION: GB PL/0242/0301 19950718

TOPAMAX (topiramate): Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What is TOPAMAX and how is it sold commercially?

TOPAMAX is the brand name for topiramate, an oral antiepileptic drug. In the US, it is historically sold by multiple manufacturers under the brand, with a long-running shift to generic topiramate over time.

Core regulated use-cases (US labeling)

• Epilepsy: adjunctive therapy for seizures in adults and pediatric patients (age dependent by indication), and monotherapy where applicable.
• Migraine prophylaxis: prevention of migraine in adults.

Commercial implication

• The market is a blend of (1) persistent demand for chronic epilepsy control and (2) cyclical demand for migraine prevention, with pricing dominated by generic competition once patent exclusivity ended.

How has market pricing and revenue shifted under generic erosion?

Topiramate is a mature molecule with broad generic penetration. The financial trajectory follows a classic pattern for branded small-molecule neurology drugs: early premium pricing during exclusivity, then sustained revenue compression after generic launches.

Observed market reality

• Generic topiramate uptake has been extensive across payers and channels.
• Branded TOPAMAX pricing power typically declines sharply after generic penetration.
• The residual branded market is usually supported by payer restrictions, patient-physician preferences in select cases, and brand loyalty where it persists.

What that means for financials

• As generic share rises, branded unit volumes typically fall.
• Remaining branded volumes increasingly price at or near generic parity, driving revenue decline even when prescriptions stabilize at the class level.

What drives demand resilience for topiramate (despite generics)?

Even under aggressive generic competition, topiramate often shows baseline demand resilience because of clinical usage patterns in neurology.

Key demand drivers

• Chronic use in epilepsy: long-duration treatment reduces abrupt demand drops.
• Migraine prophylaxis fit: topiramate is among commonly used options; switching costs exist at the patient level.
• Titration and stability: neurologists often maintain regimens once tolerated, even when generics are available.

Key friction points

• Therapy substitution: neurologists can switch patients to other antiepileptics or migraine preventives if tolerability issues emerge.
• Payer protocol dynamics: step therapy and formulary management can channel patients toward the lowest-cost equivalent.

How does the competitive landscape affect TOPAMAX’s pricing?

Topiramate competes in two relevant “baskets”:

1. Antiepileptics for seizure control
2. Migraine preventives (with both older generics and newer branded therapies)

Competition structure

• Within-class: generic topiramate is the dominant commercial substitute.
• Cross-class for migraine: CGRP-pathway preventives and other oral prophylactics pressure utilization.
• Cross-class for epilepsy: a wide antiepileptic portfolio enables substitution if efficacy or tolerability differ.

Net effect on brand economics

• Branded TOPAMAX faces structural pricing pressure from generics and cross-class formulary shifting.
• Any brand pricing premium tends to erode as payer contracting and patient conversion accelerate.

What does the likely financial trajectory look like over time?

A realistic financial trajectory for TOPAMAX aligns with branded small-molecule lifecycle dynamics:

• Early period: higher price per unit, meaningful brand revenue contribution.
• Transition: loss of exclusivity drives generic entry, with rapid share dilution.
• Mature period: revenue becomes largely maintenance-level, supported by switching frictions and specialty/payer exceptions, then declines or stabilizes at a lower base.

Financial trajectory framework (brand vs. class)

Phase	Market condition	Brand TOPAMAX economics	Class-level outcome
Exclusivity (earlier years)	Limited generic supply	Higher net price and higher brand share	Growth tied to adoption
Post-generic entry	Broad generic availability	Revenue compression via price erosion and volume loss	Total prescriptions may stabilize
Mature/generic dominant	Formulary favors low-cost equivalents	Smaller residual branded revenue base	Class demand persists but pays less

(This framework matches the documented behavior of topiramate branding in a mature generic marketplace.)

What metrics matter most to investors tracking TOPAMAX?

For decision-making, the revenue and profit outlook is driven less by molecule innovation and more by market structure.

Primary KPIs

• Branded share of topiramate prescriptions (volume dilution signal)
• Net price vs. generic equivalents (contracting and rebate pressure)
• Script trend for the topiramate class (to separate class demand from share)
• Payer formulary positioning for migraine prophylaxis and epilepsy tiers
• Switching dynamics after new migraine entrants or epilepsy formulation changes

Interpretation guide

• If class scripts rise but branded share falls, revenue declines faster than total demand.
• If class scripts fall, branded declines accelerate, with limited ability to offset through pricing.

How do lifecycle and regulatory factors shape TOPAMAX’s long-run outlook?

TOPAMAX is not a short-cycle product. Its long-run performance depends on:

• Ongoing clinical relevance in epilepsy and migraine
• Patent and exclusivity status history that enabled generic erosion (already realized for topiramate)
• Safety/tolerability profiles that influence persistence, switching, and adherence

Clinical persistence effect

• Tolerability and dosing stability can sustain class use even as brand value falls.

Formulary effect

• Migraine prevention formularies can shift between oral agents and newer preventives, changing class demand.

Where does TOPAMAX sit in the broader migraine market?

Migraine prophylaxis is a competitive market where new entrants can alter prescribing patterns quickly.

Competitive pressures likely operating

• Newer migraine preventives can displace older oral preventives in some payer segments.
• Oral agents still retain share, especially where cost and access favor generics.

Implication for TOPAMAX

• TOPAMAX’s branded revenue is more exposed to share shifts than to class-wide clinical demand, because generic topiramate keeps the “cost floor” low.

How should you read the “brand vs. generic” story for valuation or R&D planning?

The strategic takeaway is that TOPAMAX’s economics are driven by:

• Market access and contracting
• Generic conversion and substitution
• Cross-therapy competition
• Residual brand demand pockets

For investors or R&D planners evaluating adjacent neurology opportunities:

• The topiramate example is a template for how quickly a well-known antiepileptic can lose brand premium.
• The “financial trajectory” tends to follow generic saturation rather than clinical diffusion after exclusivity.

Key Takeaways

• TOPAMAX is a mature small-molecule brand (topiramate) with demand anchored in chronic epilepsy and migraine prophylaxis but priced under sustained generic pressure.
• The financial trajectory follows generic erosion: net price compression and volume share dilution after generic entry drive sustained branded revenue decline from a higher exclusivity baseline.
• Market dynamics are payer- and formulary-led: switching, step therapy, and low-cost substitution determine branded outcomes more than clinical demand alone.
• Investable KPIs are share, net price, and class scripts: brand performance can deteriorate even if the total topiramate market holds up.
• Cross-class competition in migraine adds volatility: newer preventives can shift prescribing patterns, impacting class demand and the branded residual share.

FAQs

1. Is TOPAMAX’s market mainly driven by epilepsy or migraine?
   Both contribute, but epilepsy use typically provides steadier chronic demand, while migraine is more sensitive to formulary shifts and competitor preventives.

2. How does generic topiramate affect TOPAMAX’s revenue?
   Generic entry compresses net price and reduces branded share, driving branded revenue down even when class prescriptions remain stable.

3. What KPIs best track TOPAMAX performance?
   Branded prescription share, net price versus generic equivalents, class script trends, and formulary positioning in epilepsy and migraine tiers.

4. Does class growth guarantee brand revenue growth?
   No. Brand revenue can decline if branded share falls faster than the class grows or if net price erodes.

5. What are the biggest long-run risks to TOPAMAX economics?
   Continued payer preference for generics, cross-class displacement in migraine prophylaxis, and contracting dynamics that limit branded pricing.

---

References

[1] FDA. TOPAMAX (topiramate) prescribing information. U.S. Food and Drug Administration.
[2] FDA. Drug approvals and generic drug market context for topiramate (class-level regulatory materials). U.S. Food and Drug Administration.
[3] U.S. National Library of Medicine. Topiramate: Drug information and clinical use. MedlinePlus / PubChem resources.